116 related articles for article (PubMed ID: 30700424)
1. Response to: 'Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis' by Wallace
Kronbichler A; Kerschbaum J
Ann Rheum Dis; 2020 Apr; 79(4):e41. PubMed ID: 30700424
[No Abstract] [Full Text] [Related]
2. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
Kronbichler A; Kerschbaum J; Gopaluni S; Tieu J; Alberici F; Jones RB; Smith RM; Jayne DRW
Ann Rheum Dis; 2018 Oct; 77(10):1440-1447. PubMed ID: 29950327
[TBL] [Abstract][Full Text] [Related]
3. Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis.
Wallace ZS; Choi H; Stone JH
Ann Rheum Dis; 2020 Apr; 79(4):e40. PubMed ID: 30700422
[No Abstract] [Full Text] [Related]
4. Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov
Kronbichler A; Jayne D
Ann Rheum Dis; 2020 Feb; 79(2):e20. PubMed ID: 30700426
[No Abstract] [Full Text] [Related]
5. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.
Kronbichler A; Jayne DR; Mayer G
Eur J Clin Invest; 2015 Mar; 45(3):346-68. PubMed ID: 25627555
[TBL] [Abstract][Full Text] [Related]
6. [Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].
Dábague Guzmán J; Pedroza Granados J; Zúñiga Varga J
Reumatol Clin; 2011 Dec; 7 Suppl 3():S37-40. PubMed ID: 22119277
[TBL] [Abstract][Full Text] [Related]
7. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis.
Thery-Casari C; Euvrard R; Mainbourg S; Durupt S; Reynaud Q; Durieu I; Belot A; Lobbes H; Cabrera N; Lega JC
Autoimmun Rev; 2020 May; 19(5):102505. PubMed ID: 32173512
[TBL] [Abstract][Full Text] [Related]
8. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.
Cohen Tervaert JW
Curr Opin Rheumatol; 2018 Jul; 30(4):388-394. PubMed ID: 29621029
[TBL] [Abstract][Full Text] [Related]
9. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
10. The complications of vasculitis and its treatment.
King C; Harper L; Little M
Best Pract Res Clin Rheumatol; 2018 Feb; 32(1):125-136. PubMed ID: 30526892
[TBL] [Abstract][Full Text] [Related]
11. Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine.
Novikov PI; Bulanov NM; Zykova AS; Moiseev SV
Ann Rheum Dis; 2020 Feb; 79(2):e19. PubMed ID: 30472653
[No Abstract] [Full Text] [Related]
12. A case of probable trimethoprim-sulfamethoxazole induced circulating antineutrophil cytoplasmic antibody-positive small vessel vasculitis.
Woodring T; Abraham R; Frisch S
Dermatol Online J; 2017 Aug; 23(8):. PubMed ID: 29469750
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for ANCA-associated vasculitis in the setting of severe infection.
Gregersen JW; Chaudhry A; Jayne DR
Scand J Rheumatol; 2013; 42(3):207-10. PubMed ID: 23286789
[TBL] [Abstract][Full Text] [Related]
14. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis.
Asamiya Y; Moriyama T; Takano M; Iwasaki C; Kimura K; Ando Y; Aoki A; Kikuchi K; Takei T; Uchida K; Nitta K
Intern Med; 2010; 49(15):1587-91. PubMed ID: 20686295
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.
Nagafuchi H; Atsumi T; Hatta K; Muso E; Takeno M; Yamada H; Ozaki S
Mod Rheumatol; 2015 Jul; 25(4):603-8. PubMed ID: 25496405
[TBL] [Abstract][Full Text] [Related]
17. Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange.
Sagmeister MS; Weiss M; Eichhorn P; Habicht A; Habersetzer R; Fischereder M; Schönermarck U
BMC Nephrol; 2018 Oct; 19(1):270. PubMed ID: 30340563
[TBL] [Abstract][Full Text] [Related]
18. No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses.
Tan BK; Crabol Y; Tasse J; Laurent F; Nekkab N; Vinter C; Puéchal X; Guillevin L
Rheumatology (Oxford); 2020 Jan; 59(1):77-83. PubMed ID: 31834404
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
